Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study.
Journal: Circulation
Published: March 29, 2026
The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification.
Journal: Clinical and translational science
Published: December 17, 2025
Sotatercept Safety and Efficacy in Intermediate- to Low-Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.
Journal: Chest
Published: December 03, 2025
Comorbidities and Events of Clinical Interest in Patients with Pulmonary Arterial Hypertension (PAH): Analysis of Real-World Data.
Journal: Pulmonary circulation
Published: October 22, 2025
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
Journal: The New England journal of medicine
Published: September 30, 2025
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.
Journal: The New England journal of medicine
Published: April 01, 2025
Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study.
Journal: Therapeutic advances in respiratory disease
Published: September 05, 2024
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: August 23, 2024
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies.
Journal: The European respiratory journal
Published: July 22, 2024
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
Journal: The Lancet. Respiratory medicine
Published: November 06, 2020
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Journal: The Lancet. Respiratory medicine
Published: April 30, 2020
Last Updated: 09/26/2026